News | August 02, 2011

PET Census: Slower But Continued Growth in PET Patient Studies (2008 to 2010)

August 2, 2011 – An estimated 1.7 million clinical positron emission tomography (PET) patient studies were performed in the United States in 2010, according to a report just released by IMV Medical Information Division. These PET studies were performed in 2,085 hospital and non-hospital sites, using fixed or mobile PET/computed tomography (CT) or PET scanners.

“The estimated 1,744,000 clinical PET patient studies performed in 2010 represent a 14.7 percent increase over IMV’s estimate of 1,520,800 patient studies performed in 2008, for an average annual growth rate of 7.1 percent over the two years,” said Lorna Young, senior director of market research at IMV. “This represents a slowing in the annual growth rate for PET patient studies, as the average annual rate between 2005 and 2008 was 10.4 percent. However, the annual 7 percent rate for procedures is still a significant growth rate, in an era of increased scrutiny of third-party insurers in their pre-authorization processes.”

Currently, PET technology is utilized primarily for oncology applications, which comprise 95 percent of the PET studies. Neurology and cardiology applications make up the remaining 5 percent, which are likely to become a larger proportion of the studies to be performed, as other radiopharmaceutical tracers, such as PET agents for Alzheimer’s, become approved for clinical use.

“In parallel with the continued evolution of the clinical utility of PET, the number of sites using fixed PET technology is increasing access to PET imaging. Although the number of sites performing PET imaging using fixed or mobile PET increased only 4 percent from 2,000 sites in 2008 to the current 2,085 sites, the mix of sites using fixed units versus mobile PET services has dramatically shifted. Over half of the sites, 1,150 sites, now use fixed PET imaging units, compared to one-third of the sites that were doing PET imaging back in 2003. With this increased access, the median waiting time for a scheduled outpatient appointment at sites using fixed or mobile PET or PET/CT scanners is four days, down from seven days in 2001,” Young said.

“Also, we see a sizable shift in sites using fixed PET/CTs compared to fixed PET scanners. When PET/CT came into the market around 2003, it was adopted rapidly, due to its unparalleled capability to image both anatomical structures and metabolic activity. In 2003, one-third of the installed base was PET/CT scanners, but now, about 90 percent of the fixed units are PET/CTs,” Young said.

“The market for PET scanners was affected by the general economic downturn in 2008. That, coupled with the near-completion of the replacement of the PET-only scanners with PET/CTs, may result in a slow recovery for unit sales. However, about 45 percent of the PET imaging sites currently use mobile services, and they may purchase their first fixed unit as they grow their volume and referrals. Newly introduced technology such as PET/magnetic resonance (MR) may stimulate the demand for additional units in the larger PET centers. Over the next few years, about half of the PET scanner demand will come from first buyers, who are primarily mobile users, about one-third will be replacement buyers and the remaining purchases will be for additional units.”

The report describes trends in PET and PET/CT patient studies by procedure type, PET and PET/CT installed base by manufacturer and year of installation, planned purchases and market scenarios for unit sales through 2015, radiopharmaceutical utilization and expenditures by supplier, and site operations characteristics. Other highlights include:

The top five PET oncology applications are for respiratory, breast cancer, lymphoma and colorectal cancer.

Ninety-four percent of the PET patient studies used radiopharmaceuticals purchased from an outside supplier and 6 percent were obtained from cyclotrons on site.

The five states with the highest PET patient study volume are Florida, California, New York, Texas and Pennsylvania.

IMV’s 2011 PET and PET/CT Census Database provides comprehensive profiles of the identified PET imaging sites in the United States. The database can be licensed by qualified subscribers and includes contact and site-specific information. IMV's 2011 PET Imaging Market Summary Report is available with the database license, or as a separate purchase.

For more information: www.PETReport.imvinfo.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init